Clinical Trial Update: Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer [NA]

View source ↗

Summary

The study evaluating circulating tumor DNA–based minimal residual disease detection in early-stage breast cancer is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: City of Hope Medical Center | Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | NA | Status: SUSPENDED